Home › Acute Biphenotypic Leukemia › Georgia
Acute Biphenotypic Leukemia clinical trials in Georgia
9 studies for Acute Biphenotypic Leukemia are looking for participants at sites in Georgia.
Cities in Georgia
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
RecruitingPhase 2
365 Days · All sexes · Updated Oct 27, 2026 · NCT06317662Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Children's Healthcare of Atlanta, Atlanta
RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Oct 22, 2026 · NCT06177067A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Emory Winship Cancer Institute, Atlanta
RecruitingPhase 1/2
30 Days · All sexes · Updated Oct 9, 2026 · NCT04065399A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- Emory University, Atlanta
RecruitingPhase 1
Ages 12 to 78 · All sexes · Updated Sep 29, 2026 · NCT03802695Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
- Augusta University Medical Center, Augusta
- Atrium Health Navicent, Macon
- and 1 more
RecruitingPhase 3
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
- Memorial Health University Medical Center, Savannah
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241Venetoclax Basket Trial for High Risk Hematologic Malignancies
- Children's Healthcare of Atlanta at Arthur M. Blank Hospital, Atlanta
RecruitingPhase 1
Ages 1 to 40 · All sexes · Updated Mar 12, 2026 · NCT05292664Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
- Emory University - WINSHIP Cancer Center, Atlanta
- Emory University, Children's Healthcare of Atlanta, Atlanta
RecruitingPhase 1
Ages 12 and older · All sexes · Updated Jan 8, 2026 · NCT04872478Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's Healthcare of Atlanta, Emory University, Atlanta
RecruitingPhase 1
Ages 1 to 21 · All sexes · Updated Dec 6, 2024 · NCT05476770From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.